The ability of WNT5A to inhibit MITF, a downstream target of β-catenin, may be one cause of resistance in BRAFi-treated melanoma patients, as MITF depletion can activate EGFR signaling, which can confer BRAFi resistance [98]. Here, EGFR is linked to melanoma.